InvestorsHub Logo
Followers 30
Posts 24851
Boards Moderated 1
Alias Born 01/04/2004

Re: None

Thursday, 04/21/2016 4:05:21 PM

Thursday, April 21, 2016 4:05:21 PM

Post# of 1319
From article in the Deal.

Higgins noted that Trevena Inc. could, like Synergy, be a target for Allergan, if it has positive data in phase 2B of clinical trials. Allergan already owns an option in the acute heart failure drug company, and would pay $65 million to exercise marketing and development rights. Higgins said the company could go for around $1 billion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TRVN News